Literature DB >> 26727289

Immunomodulation mediated through Leishmania donovani protein disulfide isomerase by eliciting CD8+ T-cell in cured visceral leishmaniasis subjects and identification of its possible HLA class-1 restricted T-cell epitopes.

Ajay Amit1, Manas R Dikhit1,2, Vijay Mahantesh1,3, Rajesh Chaudhary1, Ashish Kumar Singh1,4, Ashu Singh3, Shubhankar Kumar Singh5, V N R Das6, Krishna Pandey6, Vahab Ali7, Shyam Narayan5, Ganesh C Sahoo2, Pradeep Das8, Sanjiva Bimal1.   

Abstract

Protein disulphide isomerase (PDI) is one of the key enzymes essential for the survival of Leishmania donovani in the host. Our study suggested that PDI is associated with the generation of Th1-type of cellular responses in treated Visceral leishmaniasis (VL) subjects. The stimulation of Peripheral blood mononuclear cells (PBMCs) with recombinant Protein Disulphide Isomerase upregulated the reactive oxygen species generation, Nitric oxide release, IL12 and IFN-γ production indicating its pivotal role in protective immune response. Further, a pre-stimulation of PBMCs with Protein disulphide isomerase induced a strong IFN-γ response through CD8+ T cells in treated VL subjects. These findings also supported through the evidence that this antigen was processed and presented by major histocompatibility complex class I (MHC-1) dependent pathway and had an immunoprophylactic potential which can induce CD8+ T cell protective immune response in MHC class I dependent manner against VL. To find out the possible epitopes that might be responsible for CD8+ T cell specific IFN-γ response, computational approach was adopted. Six novel promiscuous epitopes were predicted to be highly immunogenic and can be presented by 32 different HLA allele to CD8+ T cells. Further investigation will explore more about their immunological relevance and usefulness as vaccine candidates.

Entities:  

Keywords:  CD8+ T cells; Leishmania donovani; VL; immunoinformatic; protein disulphide isomerase

Mesh:

Substances:

Year:  2016        PMID: 26727289     DOI: 10.1080/07391102.2015.1134349

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  7 in total

Review 1.  Association of HLA class I and II genes with cutaneous leishmaniasis: a case control study from Sri Lanka and a systematic review.

Authors:  Nilakshi Samaranayake; Sumadhya D Fernando; Nilaksha F Neththikumara; Chaturaka Rodrigo; Nadira D Karunaweera; Vajira H W Dissanayake
Journal:  BMC Infect Dis       Date:  2016-06-14       Impact factor: 3.090

2.  Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species.

Authors:  Jéssica Cristina Dos Santos; Bas Heinhuis; Rodrigo Saar Gomes; Michelle S M A Damen; Fernando Real; Renato A Mortara; Samuel T Keating; Charles A Dinarello; Leo A B Joosten; Fátima Ribeiro-Dias
Journal:  PLoS Negl Trop Dis       Date:  2017-02-27

3.  Modulation of the immune response and infection pattern to Leishmania donovani in visceral leishmaniasis due to arsenic exposure: An in vitro study.

Authors:  Ghufran Ahmed; Ajit K Thakur; Sanjay K Chaturvedi; Pushkar Shivam; Fauzia Jamal; Manish K Singh; Sanjiva Bimal; Subhankar K Singh; Sunil K Choudhary; Pradeep Das; Shyam Narayan
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

4.  PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.

Authors:  Hao Zhang; Jialin He; Ziyu Dai; Zeyu Wang; Xisong Liang; Fengqiong He; Zhiwei Xia; Songshan Feng; Hui Cao; Liyang Zhang; Quan Cheng
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

Review 5.  Peptide Vaccines for Leishmaniasis.

Authors:  Rory C F De Brito; Jamille M De O Cardoso; Levi E S Reis; Joao F Vieira; Fernando A S Mathias; Bruno M Roatt; Rodrigo Dian D O Aguiar-Soares; Jeronimo C Ruiz; Daniela de M Resende; Alexandre B Reis
Journal:  Front Immunol       Date:  2018-05-11       Impact factor: 7.561

6.  The potential HLA Class I-restricted epitopes derived from LeIF and TSA of Leishmania donovani evoke anti-leishmania CD8+ T lymphocyte response.

Authors:  Manas Ranjan Dikhit; Sushmita Das; Vijaya Mahantesh; Akhilesh Kumar; Ashish Kumar Singh; Budheswar Dehury; Ajaya Kumar Rout; Vahab Ali; Ganesh Chandra Sahoo; Roshan Kamal Topno; Krishna Pandey; V N R Das; Sanjiva Bimal; Pradeep Das
Journal:  Sci Rep       Date:  2018-09-21       Impact factor: 4.379

7.  Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.

Authors:  Sarra Hamrouni; Rachel Bras-Gonçalves; Abdelhamid Kidar; Karim Aoun; Rym Chamakh-Ayari; Elodie Petitdidier; Yasmine Messaoudi; Julie Pagniez; Jean-Loup Lemesre; Amel Meddeb-Garnaoui
Journal:  PLoS Negl Trop Dis       Date:  2020-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.